Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-017-1267-3
Published Online: 2017-03-09
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huizinga, T. W. J.
Batalov, A.
Stoilov, R.
Lloyd, E.
Wagner, T.
Saurigny, D.
Souberbielle, B.
Esfandiari, E.
Funding for this research was provided by:
Takeda Pharmaceutical Company